首页> 外文期刊>Cell stress & chaperones >Superoxide dismutase activity as a predictor of adverse outcomes in patients with nonischemic dilated cardiomyopathy
【24h】

Superoxide dismutase activity as a predictor of adverse outcomes in patients with nonischemic dilated cardiomyopathy

机译:超氧化物歧化酶活性可预测非缺血性扩张型心肌病患者不良预后

获取原文
           

摘要

Oxidative stress contributes to progression of heart failure (HF). The present study analyzed the efficacy of the activities of superoxide dismutase (SOD) and its isoenzymes (CuZnSOD and MnSOD) as prognostic factors in dilated cardiomyopathy. The usefulness of activities of total SOD, MnSOD, and CuZnSOD was assessed, taking into account clinical, echocardiographic, and laboratory parameters as risk predictors of long-term clinical outcomes (death, heart transplant, combined end point) in 109 patients with nonischemic dilated cardiomyopathy (NIDCM) in this study with a 5-year follow-up. Regression analysis showed that total serum SOD activity was a predictor of worse long-term clinical outcome even after adjustment for NT-proBNP, hemoglobin, sodium, creatinine clearance, left ventricular ejection fraction (LVEF), BMI, and NYHA class (LVEF: HR 1.059, 95% CI 1.007–1.114, P ?=?0.026; BMI: HR 1.073, 95% CI 1.021–1.126, P ?=?0.005; NYHA: HR 1.073, 95% CI 1.022–1.126, P ?=?0.005). MnSOD and CuZnSOD activities were also predictors of worse long-term clinical outcome even after adjustment for laboratory parameters and BMI or NYHA class; however, after adjustment for LVEF, a borderline statistical significance was achieved (LVEF: HR 1.054, 95% CI 0.993–1.119, P ?=?0.081 [MnSOD]; HR 1.092, 95% CI 0.989–1.297, P ?=?0.082 [CuZnSOD]). Increased activities of total serum SOD and its isoenzymes in NIDCM patients correspond with a poor prognosis and may have prognostic value in the prediction of long-term clinical outcomes. In conclusion, the present study shows that serum SOD activity may be a useful predictor of adverse outcome in HF.
机译:氧化应激会导致心力衰竭(HF)的进展。本研究分析了超氧化物歧化酶(SOD)及其同功酶(CuZnSOD和MnSOD)活性作为扩张型心肌病预后因素的功效。评估了总SOD,MnSOD和CuZnSOD活性的有用性,并考虑了临床,超声心动图和实验室参数作为109例非缺血性扩张型患者长期临床结果(死亡,心脏移植,联合终点)的风险预测指标这项研究对心肌病(NIDCM)进行了5年的随访。回归分析表明,即使调整了NT-proBNP,血红蛋白,钠,肌酐清除率,左心室射血分数(LVEF),BMI和NYHA级(LVEF:HR),血清总SOD活性仍是长期临床结局恶化的预测指标1.059,95%CI 1.007–1.114,P?=?0.026; BMI:HR 1.073,95%CI 1.021–1.126,P?= 0.005; NYHA:HR 1.073,95%CI 1.022–1.126,P?= 0.005 )。即使调整了实验室参数和BMI或NYHA等级,MnSOD和CuZnSOD活性也是长期临床结局恶化的预兆。然而,在调整LVEF后,达到了统计学上的临界值(LVEF:HR 1.054,95%CI 0.993-1.119,P?=?0.081 [MnSOD]; HR 1.092,95%CI 0.989-1.297,P?= 0.082 [CuZnSOD]。 NIDCM患者总血清SOD及其同工酶活性的增加预后较差,可能在预测长期临床预后方面具有预后价值。总之,本研究表明血清SOD活性可能是HF不良结局的有用预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号